Data from a phase 1/2 trial in patients with several subtypes of HER3 expressing metastatic breast cancer featured as oral presentation at ASCO First presentation of phase 1 data from a cohort
Immunocore Holdings Limited: Immunocore Reports First Quarter 2021 Financial Results
Launched includes
$287 million in net proceeds from initial public offering and concurrent private placement in February 2021
Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced its results for the quarter ended March 31, 2021.
Highlights for the quarter included the presentation of the Phase 3 randomized data from the Company s lead candidate tebentafusp in the plenary clinical trial session at the American Association for Cancer Research (AACR) Annual Meeting, the launch of a global early access program for tebentafusp, and the successful completion of the Company s initial public offering resulting in net proceeds of $287 million.
Immunocore Limited: Immunocore announces key appointments to management and Board
Ralph Torbay appointed Head of Commercial to spearhead the launch of tebentafusp
Dr. Roy S. Herbst appointed as a Non-Executive Director to the Board
OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US - 16 February 2021 - Immunocore Holdings plc (Nasdaq: IMCR), (or the Company or Immunocore ), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announces the appointment of Ralph Torbay as its new Head of Commercial and the appointment of Dr. Roy S. Herbst as a member of its Board of Directors, effective January 28, 2021.